Compare OPRA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRA | TRVI |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2018 | 2019 |
| Metric | OPRA | TRVI |
|---|---|---|
| Price | $17.16 | $15.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $22.75 | $21.55 |
| AVG Volume (30 Days) | 453.0K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.29 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.71 | $5.38 |
| 52 Week High | $21.06 | $14.75 |
| Indicator | OPRA | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 71.06 | 77.85 |
| Support Level | $15.55 | $10.07 |
| Resistance Level | $17.72 | N/A |
| Average True Range (ATR) | 0.58 | 0.92 |
| MACD | 0.25 | 0.30 |
| Stochastic Oscillator | 90.53 | 91.68 |
Opera Ltd is a world-wide internet brand with a large, engaged, and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its browser's features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. Geographically, the company generates maximum revenue from the United States, followed by Singapore, Nigeria, Russia, and other locations.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.